Nurix Therapeutics is a San Francisco-based biotechnology company that is revolutionizing the field of protein modulation. With a focus on targeted protein degradation, their innovative pipeline of medicines aims to empower the body to fight diseases, particularly cancer, by activating or inhibiting the natural process of protein degradation.
Using their powerful DELigase platform, Nurix is developing a range of small molecule drugs that harness the activity of E3 ligases, a class of enzymes, to degrade specific proteins within cells. Their unique approach also includes targeted protein elevation, which allows for the modulation of protein levels, setting them apart in the field of protein modulation.
Generated from the website